Elephas

Elephas Biosciences Corporation, founded in 2019 and headquartered in Madison, Wisconsin, specializes in oncology diagnostics. The company has developed a live tumor imaging platform that preserves the tumor microenvironment, enabling the assessment of tumor responses to immunotherapies. This approach aims to predict patient-specific responses, thereby enhancing personalized treatment strategies and accelerating drug development.

Elephas has attracted significant investment from a diverse group of investors. Notable backers include Venture Investors Health Fund, State of Wisconsin Investment Board (SWIB), Northpond Ventures, ARCH Venture Partners, Sands Capital, Moore Strategic Ventures, Tao Invest, and WARF Ventures. In January 2024, the company raised $55 million in a Series C funding round led by Venture Investors Health Fund and SWIB.

What sets Elephas apart is its innovative use of live tumor imaging to maintain the integrity of the tumor microenvironment, providing a more accurate representation of how tumors respond to treatments. This methodology addresses the challenge of predicting immunotherapy outcomes, which can vary significantly among patients. By offering insights into individual tumor behavior, Elephas facilitates the development of tailored therapeutic approaches, potentially improving patient outcomes and reducing unnecessary treatments.

In the artificial intelligence landscape, Elephas operates within the category of AI-driven medical diagnostics. The company leverages advanced imaging techniques and data analysis to enhance the precision of cancer diagnostics and treatment planning, contributing to the advancement of personalized medicine.

For more information, please visit elephas.com.

To claim this startup page, go to the Contact page and send us a message with your full name, startup name, job title, and startup email address. We will review your request and get back to you. Once verified, you can update your startup information.